Thursday - April 30, 2026
Saphnelo Approved in the U.S. for Subcutaneous Self-Administration as a New Autoinjector for the Treatment of Systemic Lupus Erythematosus
April 28, 2026
WILMINGTON, Delaware, April 28 (TNSjou) -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

First-in-class SAPHNELO Pen now offers greater flexibility and convenience,

reaching a wider group of patients

*

AstraZeneca's SAPHNELO(R) (anifrolumab-fn . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products